Abstract

Review Article

Dapt Review

KARACA Özkan*, KARASU Mehdi, KOBAT Mehmet A and KIVRAK Tarık

Published: 25 March, 2020 | Volume 5 - Issue 1 | Pages: 060-066

Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) compared with aspirin monotherapy but at the expense of an increased risk of significant bleeding. Among patients with stable CAD undergoing PCI with drug-eluting stents (DES), shorter duration of DAPT (3–6 months) were shown non-inferior to 12 or 24 months duration concerning MACE but reduced the rates of major bleeding? Contrariwise, prolonged DAPT durations (18–48 months) reduced the incidence of myocardial infarction and stent thrombosis, but at the cost of an increased risk of majör bleeding and all-cause mortality. Until more evidence becomes available, the choice of optimal DAPT regimen and duration for patients with CAD requires a tailored approach based on the patient clinical presentation, baseline risk profile and management strategy. Patients with acute coronary syndromes (ACS) and a history of atrial fibrillation (AF) have indications for both dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC). Triple therapy (TT), the combination of DAPT and OAC, is recommended in guidelines. This article provides a contemporary state-of-the-art review of the current evidence on DAPT for secondary prevention of patients with CAD and its future perspectives.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001088 Cite this Article Read Full Article PDF

Keywords:

Coronary arteries; Antiplatelets; Intervention

References

  1. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2017; 53: 34-78. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29045581
  2. Gwon HC1, Hahn JY, Park KW, Song YB, Chae IH, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125: 505-513. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22179532
  3. Palmerini T, Bacchi Reggiani L1, Della Riva D1, Romanello M1, Feres F2, et al. Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting. J Am Coll Cardiol. 2017; 69: 2011-2022. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28427576
  4. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016; 68: 1082-1115. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27036918
  5. Jeppsson A, Petricevic M, Kolh P, Valgimigli M. 2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Oxford University Press. 2017.
  6. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000; 102: 624-629. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10931801
  7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
  8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19717846
  9. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179-1189. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15758000
  10. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials: Elsevier. 2009.
  11. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34: 2949-3003. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23996286
  12. Green D. CAPRIE trial. The Lancet. 349(9048). 354-355.
  13. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17498584
  14. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084-1089. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8598866
  15. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998; 98: 2126-2132. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9815866
  16. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, et al. Impact of bleeding on mortality after percutaneous coronary intervention: results from a patient-level pooled analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trials. JACC: Cardiovascular Interventions. 2011 4: 654-664. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21700252
  17. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35: 2541-2619. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25173339
  18. Lorenz RL, Schacky CV, Weber M, Meister W, Kotzur J, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation. The Lancet. 1994; 323(8389). 1261-1264. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6144975
  19. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet. 2010; 376(9748): 1233-1243. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20817281
  20. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010; 363: 930-942. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20818903
  21. Berger JS. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Am J Cardiol. 2013; 112: 737-745. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23751937
  22. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64: e1-e76. https://www.ncbi.nlm.nih.gov/pubmed/24685669
  23. Karjalainen PP1, Porela P, Ylitalo A, Vikman S, Nyman K, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007; 28: 726-732. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17267456
  24. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and haemostasis. 2011; 106: 571-584. https://www.ncbi.nlm.nih.gov/pubmed/21785808
  25. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35: 3155-3179. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25154388
  26. Fosbol EL, Wang TY, Li S, Piccini J, Lopes RD, et al. Warfarin use among older atrial fibrillation patients with non–ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. Am Heart J. 2013; 166: 864-870. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24176442
  27. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013; 62: 981-989. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23747760
  28. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20299623
  29. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61: e78-e140. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23256914
  30. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 60: 645-681. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22809746

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

Recently Viewed

  • Improvement of the Deterioration of the Gut Microbiota Due to High-fat, High-sucrose Diet Acylated Steryl-β-glycosides Intake
    Masaki Iji, Kuniyuki Yamada, Yuta Yamane, Chihiro Watanabe, Kazuhito Takemoto, Mamoru Tanaka, Yuichiro Takei, Takako Miyaue, Yoichi Miura and Hiroyuki Watanabe* Masaki Iji, Kuniyuki Yamada, Yuta Yamane, Chihiro Watanabe, Kazuhito Takemoto, Mamoru Tanaka, Yuichiro Takei, Takako Miyaue, Yoichi Miura, Hiroyuki Watanabe*. Improvement of the Deterioration of the Gut Microbiota Due to High-fat, High-sucrose Diet Acylated Steryl-β-glycosides Intake. Arch Food Nutr Sci. 2023: doi: 10.29328/journal.afns.1001051; 7: 065-069
  • Calciphylaxis in Hemodialysis
    Luca Sgarabotto*, Paola Baldini Anastasio, Nicola Marchionna and Monica Zanella Luca Sgarabotto*, Paola Baldini Anastasio, Nicola Marchionna, Monica Zanella. Calciphylaxis in Hemodialysis. J Clini Nephrol. 2023: doi: 10.29328/journal.jcn.1001107; 7: 044-046
  • Impact of COVID-19 on Laboratory Health Staff in an Indian Tertiary Care Hospital
    Pooja Sharma, Anita Tahlan*, Anshu Palta and Monica Gupta Pooja Sharma, Anita Tahlan*, Anshu Palta, Monica Gupta. Impact of COVID-19 on Laboratory Health Staff in an Indian Tertiary Care Hospital. Arch Pathol Clin Res. 2023: doi: 10.29328/journal.apcr.1001034; 7: 001-006
  • Variation in Genuine Handwriting While Writing on an Unusual Surface
    Nisha Potle, Sakshi Hemant Chavan, Yash Hari Kekane, Snehal Umesh Tembhurne, Nitin Pandey* and Yash Ranjeet dalvi Nisha Potle, Sakshi Hemant Chavan, Yash Hari Kekane, Snehal Umesh Tembhurne, Nitin Pandey*, Yash Ranjeet dalvi. Variation in Genuine Handwriting While Writing on an Unusual Surface. J Forensic Sci Res. 2023: doi: 10.29328/journal.jfsr.1001046; 7: 025-033
  • Magnets, Gradients, and RF Coils of MR Scanners
    Željko Đ Vujović* Željko Đ Vujović*. Magnets, Gradients, and RF Coils of MR Scanners. Int J Phys Res Appl. 2023: doi: 10.29328/journal.ijpra.1001062; 6: 128-135

Read More

Most Viewed

Read More

Help ?